Mumps – Pipeline Review, H1 2019 Featuring Cadila Healthcare, GlaxoSmithKline and Sinovac Biotech – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Mumps
– Pipeline Review, H1 2019”
drug pipelines has been added to ResearchAndMarkets.com’s
offering.

Mumps – Pipeline Review, H1 2019 provides comprehensive
information on the therapeutics under development for Mumps (Infectious
Disease), complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type.

The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases. The Mumps (Infectious Disease) pipeline guide
also reviews of key players involved in therapeutic development for
Mumps and features dormant and discontinued projects.

The guide covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Phase III, Phase II, Phase I and IND/CTA Filed stages are 2, 1, 2 and
1 respectively. Similarly, the Universities portfolio in Phase II and
Preclinical stages comprises 1 and 1 molecules, respectively.

Mumps (Infectious Disease) pipeline guide helps in identifying and
tracking emerging players in the market and their portfolios, enhances
decision making capabilities and helps to create effective counter
strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic
    landscape of Mumps (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Mumps (Infectious
    Disease) by companies and universities/research institutes based on
    information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of
    development ranging from pre-registration till discovery and
    undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline
    products which comprise, product description, descriptive licensing
    and collaboration details, R&D brief, MoA & other developmental
    activities.
  • The pipeline guide reviews key companies involved in Mumps (Infectious
    Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Mumps (Infectious Disease) therapeutics
    based on mechanism of action (MoA), drug target, route of
    administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued
    pipeline projects.
  • The pipeline guide reviews latest news related to pipeline
    therapeutics for Mumps (Infectious Disease)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and
    insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio
    and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under
    development for Mumps (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of
    leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players
    and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding
    Mumps (Infectious Disease) pipeline depth and focus of Indication
    therapeutics.
  • Develop and design in-licensing and out-licensing strategies by
    identifying prospective partners with the most attractive projects to
    enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects
    and understand from the know-how what drove them from pipeline.

Companies Mentioned

  • Cadila Healthcare Ltd.
  • GlaxoSmithKline PLC
  • Sinovac Biotech Ltd.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/134okh

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Infectious
Diseases Drugs